Share
Journal Information
Special content about coronavirus SARS-CoV-2 (COVID-19) in Endocrinología y Nutrición (English Edition)
Estimation of the economic and health impact of complications of type 2 diabetes mellitus in the autonomous community of Madrid (Spain)
Francisco Arrieta, Carlos Rubio-Terrés, Darío Rubio-Rodríguez, Ana Magaña, Marbella Piñera, Pedro Iglesias, Pedro Nogales, Alfonso Calañas, Blanca Novella, José Ignacio Botella-Carretero, Carlos Debán, Isabel Zamarrón, Gustavo Mora, José Antonio Balsa, Clotilde Vázquez
10.1016/j.endoen.2014.03.009
Endocrinol Nutr 2014;61:193-201
Full text access
Degludec, a new ultra-long-acting basal insulin for the treatment of diabetes mellitus type 1 and 2: Advances in clinical research
Manuel Muñoz Torres
10.1016/j.endoen.2014.02.010
Endocrinol Nutr 2014;61:153-9
Full text access
Metabolic control and chronic complications during a 3-year follow-up period in a cohort of type 2 diabetic patients attended in primary care in the community of Madrid (Spain)
Francisco Arrieta, Marbela Piñera, Pedro Iglesias, Pedro Nogales, Miguel Angel Salinero-Fort, Juan Carlos Abanades, José Ignacio Botella-Carretero, Alfonso Calañas, José Antonio Balsa, Isabel Zamarrón, Adela Rovira, Clotilde Vázquez
10.1016/j.endoen.2013.09.002
Endocrinol Nutr 2014;61:11-7
Full text access
Quality of life and satisfaction with treatment in subjects with type 2 diabetes: Results in Spain of the PANORAMA study
Pedro DePablos-Velasco, Emilio Salguero-Chaves, Julio Mata-Poyo, Beatriz DeRivas-Otero, Ricardo García-Sánchez, Pablo Viguera-Ester
10.1016/j.endoen.2014.01.011
Endocrinol Nutr 2014;61:18-26
Full text access
Joint Position Statement of the SEEN-SECO-SEEDO-SED Societies on metabolic surgery for type 2 diabetes mellitus
Miguel A. Rubio, Susana Monereo, Albert Lecube, Joaquín Resa, Carlos Masdevall, Felipe de la Cruz Vigo, Mar Garrido, Albert Goday, Ignacio Llorente, Carlos Pesquera
10.1016/j.endoen.2013.12.001
Endocrinol Nutr 2013;60:547-8
Full text access
Characterization of and costs associated to the profile of patients with type 2 diabetes treated with metformin who are added a second oral antidiabetic drug: A population study
Antoni Sicras-Mainar, Beatriu Font-Ramos, Cecilia Roldán-Suárez, Ruth Navarro-Artieda, Jordi Ibáñez-Nolla
10.1016/j.endoen.2013.12.011
Endocrinol Nutr 2013;60:557-69
Full text access
Non-islet cell induced hypoglycemia by “big-IGF-2” in a patient with retroperitoneal solitary fibrous tumor and a papillary thyroid carcinoma: An unusual association
Andreea Ciudin, Albert Lecube, Cristina Hernández, Jordi Mesa, Rafael Simó
10.1016/j.endoen.2013.10.020
Endocrinol Nutr 2013;60:483-4
Full text access
Relating with monographic “Actualización terapéutica para el tratamiento de la diabetes tipo 2”
Federico Relimpio Astolfi, Villafaina Barroso, Antonio Jesús Blanco Carrasco
10.1016/j.endoen.2013.02.004
Endocrinol Nutr 2013;60:409-10
Full text access
Direct healthcare costs and clinical outcomes after insulin initiation in patients with type 2 diabetes mellitus in Spain: 24-month follow-up data from the INSTIGATE study
Tatiana Dilla, Claudia Nicolay, María Álvarez, Jesús Reviriego, Alberto Goday, Conxa Castell
10.1016/j.endoen.2012.11.008
Endocrinol Nutr 2013;60:224-34
Full text access
Switching to basal-bolus insulin therapy is effective and safe in long-term type 2 diabetes patients inadequately controlled with other insulin regimens
Irene Vinagre, Juan Sánchez-Hernández, José Luis Sánchez-Quesada, Miguel Ángel María, Alberto de Leiva, Antonio Pérez
10.1016/j.endoen.2012.11.007
Endocrinol Nutr 2013;60:249-53
Full text access
Special content about COVID-19
- Gut microbiota and type 2 diabetes mellitus
- Healthcare costs of people with type 2 diabetes mellitus in the Basque Country (Spain)
- Use of healthcare resources and costs associated to the start of treatment with injectable drugs in patients with type 2 diabetes mellitus
- Efficacy and safety of empagliflozin in combination with other oral hypoglycemic agents in patients with type 2 diabetes mellitus
Publication History